. Author manuscript; available in PMC: 2019 Jan 1.

Published in final edited form as: J Mol Cell Cardiol. 2017 Nov 17;114:175–184. doi: 10.1016/j.yjmcc.2017.11.011

Table 2.

Lidocaine reduced heart rate with no significant negative impact on cardiac function

	Control	100 μM Lidocaine	200 μM Lidocaine	300 μM Lidocaine
Heart Rate (bpm)	251.99±25.06	215.99±31.50	198.83±23.84^*	133.70±8.86^*^#^&
LVP max (mmHg)	86.34±2.98	86.12±2.28	88.25±2.52	85.17±2.97
LVP min (mmHg)	3.65±0.26	3.23±0.20	2.97±0.15	2.74±0.22
+dP/dt max (mmHg/s)	4021.66±182.27	3999.58±172.06	4112.55±149.27	3705.04±176.84
−dP/dt max (mmHg/s)	−3003.18±133.86	−2969.2±167.56	−2951.42±99.70	−2592.51±91.036
Stroke Volume (mL/mg)	0.253±0.011	0.261±0.0139	0.269±0.015	0.271±0.015

The heart rate responses to 100, 200 and 300 μM lidocaine at 10 mmHg preload and 55 mmHg afterload showed a dose-dependent gradual decrease of heart rate to ~120 bpm with no significant change in LVPmax, LVPmin, systolic (+dP/dt) and diastolic (−dP/dt) velocities, and stroke volume. N = 6 hearts.

Values are presented as mean ± SE.

P<0.05 vs. Control;

P<0.05 vs. 100 μM;

P<0.05 vs. 200 μM in Student’s t test.